25 non-profit organisations working in the fields of social welfare, the environment, and biomedical research and associated with the LegadoSolidario.org campaign inform the public about the possibility of including a donation to a cause or charity with which they identify.
According to data from 2015, only 1% of wills made in Spain included a charitable bequest.
IRB Barcelona has been awarded two ERC PoC grants to optimise and validate tools with potential clinical applications.
Angel R. Nebreda’s project seeks to develop treatments to reduce the cardiotoxicity caused by chemotherapy.
Eduard Batlle’s project will build a biobank of mouse tumour organoids with the aim to contribute to the treatment of patients with advanced colon cancer.
A project headed by Antonio Zorzano at IRB Barcelona has been awarded funding from the BBVA Foundation to explore a possible link between ageing and cancer.
Called MitoFuss, the project focuses on the mitochondrial protein Mitofusin 2.
Manuel Serrano, ICREA researcher at IRB Barcelona, is the subject of the next video in the Meet Our Scientists series: “Killing zombie cells”.
In the video, Serrano talks about the work undertaken in his lab to find compounds that can remove damaged cells from the body.
The protein CPEB4, which coordinates the expression of hundreds of genes required for neuronal activity, is altered in the brains of individuals with autism
Published in Nature, the study indicates that a defect in CPEB4 could be the link between environmental factors that alter brain development and the genes that determine susceptibility to autism
Published in Science Advances, the study shows that the TLK1 and TLK2 enzymes are critical for ensuring the copying of DNA.
Loss of TLK1 and TLK2 results in extensive DNA damage during DNA replication and in cancer cell death.
Depletion of TLK1/2 enhances the effectiveness of some chemotherapeutic agents currently being tested in clinical trials
A new computational model has allowed researchers to identify new therapeutic targets that can attack cancer cells by lowering their intracellular pH.
The study, which is the result of collaboration between IRB Barcelona, the Moffitt Cancer Center, and the University of Maryland, has been published in Nature Communications.
A team headed by Manuel Serrano at IRB Barcelona has designed a drug encapsulation system that selectively targets senescent cells.
The study paves the way for therapeutic approaches to eliminate senescent cells in many diseases, such as pulmonary fibrosis and cancer.
The scientist Roger Gomis receives funding from the “la Caixa” Foundation for a project devoted to metastatic breast cancer.